准备和优化pramipexole化固体分散剂以改善药物释放和生物可用性
Yuanyuan Ding1,2, Zhenkun Su1, Guodong Liang1
1College of Pharmacy, Inner Mongolia Medical University, Hohhot, China.
AAPS PharmSciTech
|October 31, 2025
概括
这项研究使用热挤出开发了持续释放的普拉米醇二化 (PPX) 固体分散颗粒. 这种新型配方显著提高了大鼠的PPX生物可用性和大脑积累,为帕金森病提供了有前途的治疗方法.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
- 材料科学 材料科学 材料科学
背景情况:
- 普拉米醇二化 (PPX) 是BCS I类药物,其半衰期很短,容易发生光降解.
- 由于PPX的特性,现有的配方可能缺乏剂量方便性.
- 改善PPX的药理动力学特征对于有效的帕金森病管理至关重要.
研究的目的:
- 开发使用热挤出 (HME) 的pramipexole二 (PPX) 持续释放 (SR) 固体分散 (SD) 颗粒.
- 优化配方和制备过程,以提高药物的稳定性和可控释放.
- 评估开发的PPX-SD配方的体外和体内性能.
主要方法:
- 使用乙烯纤维素 (EC) 和聚乙烯甘6000 (PEG6000) 通过HME. 制备PPX固体分散 (PPX-SD) 颗粒.
- 使用单因素实验和中央复合设计 (CCD) 优化制备参数.
- 使用SEM,DSC,PXRD和FT-IR进行PPX-SD的表征;在pH值为6.8的体外释放研究;在老鼠体内药理动力学和组织分布研究.
主要成果:
- 在最佳条件下,PPX-SD具有稳定的性能和持续释放特征.
- 鉴定证实了PPX在SD矩阵中的无形状态,具有潜在的聚合物相互作用.
- 在体外释放在pH值6.8.8时更慢,更受控制.
- 与商业配方 (Sifrol®) 相比,体内研究显示AUC0-∞增加四倍,大脑积累增加.
结论:
- 通过HME开发的PPX-SD配方表现出持续释放的特性,并显著提高了PPX的生物可用性.
- 该配方保持超和无形PPX,抑制沉并增强药物吸收.
- 这种新的PPX-SD配方为改善帕金森病治疗提供了强有力的科学基础.
相关概念视频
Bioavailability Enhancement: Drug Solubility Enhancement
210
Body:Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
210
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
188
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
188
Factors Influencing Drug Absorption: Pharmaceutical Parameters
390
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
390
Bioavailability Enhancement: Drug Permeability Enhancement
182
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
182
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
489
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
489
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
142
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
142


